Primary Immune Deficiency Disorder Clinical Trial
Official title:
A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2024 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 79 Years |
Eligibility | 1. Patients with Adenovirus infections post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with: - Increasing or persistent quantitative ADV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and/or - clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR - Medical intolerance to anti-viral therapies including: - grade 2 renal insufficiency secondary to cidofovir Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures. Performance Status > 30% (Lansky < 16 yrs and Karnofsky > 16 yrs) Age: 0.1 to 79 years Females of childbearing potential with a negative urine pregnancy test 2. Donor Eligibility Related donor available with a T-cell response to the viral MACSĀ® GMP PepTivator antigen(s) of adenovirus. a. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor > 1 HLA A, B, DR match to recipient) with a T-cell response at least to the viral MACSĀ® GMP PepTivator antigen(s) of adenovirus. AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1). AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection. 3. Patient exclusion criteria: A patient meeting any of the following criteria is not eligible for the present study: . Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients >16 years) or Lansky (patients =16 years) score =30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory adenovirus infection(s) Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment. Known hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent. Known human anti-mouse antibodies - |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital of Colorado | Aurora | Colorado |
United States | University of Colorado Denver | Aurora | Colorado |
United States | Johns Hopkins | Baltimore | Maryland |
United States | Nationwide Children's Hosptial | Columbus | Ohio |
United States | Indiana University | Indianapolis | Indiana |
United States | Children's Hospital Los Angeles | Los Angeles | California |
United States | Medical College of Wisconsin/Children's Hospital of Wisconsin | Milwaukee | Wisconsin |
United States | Children's Hospital of Pennsylvania | Philadelphia | Pennsylvania |
United States | Washington University | Saint Louis | Missouri |
United States | University of California San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
New York Medical College | Children's Hospital of Philadelphia, Indiana University, Johns Hopkins University, Medical College of Wisconsin, Nationwide Children's Hospital, University of California, Los Angeles, University of California, San Francisco, University of Colorado, Denver, Washington University School of Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Patients will be followed for adverse events following each infusion of ADV CTLs | 12 weeks after each infusion | |
Primary | Incidence of Response to Treatment (Efficacy) | Patients will be followed for improvement in viral infection by monitoring ADV PCR weekly for response to treatment with CTLs | 12 weeks after last infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03939533 -
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
|
Phase 3 | |
Recruiting |
NCT03266640 -
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
|
Phase 2 | |
Completed |
NCT01859754 -
Octagam 5% Versus Comparator Post Marketing Trial
|
||
Recruiting |
NCT03148028 -
Immunological Characteristics of Patients With PID and IBD
|
N/A | |
Active, not recruiting |
NCT04354818 -
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
|
||
Completed |
NCT03988426 -
Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases
|
Phase 3 | |
Completed |
NCT01888484 -
Study of Octanorm Subcutaneous IG in Patients With PID
|
Phase 3 | |
Completed |
NCT01131858 -
Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency
|
Phase 1/Phase 2 | |
Completed |
NCT03211689 -
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease
|
N/A | |
Terminated |
NCT01883921 -
Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
|
||
Recruiting |
NCT03266653 -
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
|
Phase 2 | |
Completed |
NCT02327351 -
TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
|
Phase 2/Phase 3 | |
Completed |
NCT03618147 -
Primary Immunodeficiency in Kuwait
|
||
Recruiting |
NCT04197596 -
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03422614 -
Pathophysiology of Inborn Immunodeficiencies
|
N/A | |
Completed |
NCT02888535 -
Intensive Care Unit and Secondary and Primary Immune Deficiency
|
||
Recruiting |
NCT04232085 -
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
|
Phase 2 | |
Active, not recruiting |
NCT03037359 -
A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
|
||
Completed |
NCT03069079 -
Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study
|
N/A | |
Recruiting |
NCT03414528 -
Identification of New Inborn Errors of Immunity
|
N/A |